Fate Therapeutics
a clinical-stage biopharmaceutical company in San Diego, United States
FATE Nasdaq
ISIN US31189P1021 SEC CIK 1434316 LEI 549300L14Q4UHOODLA90
Follow Fate Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$30.7M
+4.8% vs same quarter last year
EPS, diluted
−$0.25
+7.4% vs same quarter last year
Operating cash flow
−$27.8M
−14.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $6.6M | −$136.3M |
| FY24 | $13.6M | −$186.3M |
| FY23 | $63.5M | −$160.9M |
| FY22 | $96.3M | −$281.7M |
| FY21 | $55.8M | −$212.2M |
| FY20 | $31.4M | −$173.4M |
| FY19 | $10.7M | −$98.1M |
| FY18 | $4.7M | −$66.6M |
| FY17 | $4.1M | −$43M |
| FY16 | $4.4M | −$33.5M |
| FY15 | $2.4M | −$30M |
| FY14 | - | −$25.9M |
| FY13 | $971K | −$20.9M |
| FY12 | $2.7M | −$14.2M |
| FY11 | $1.2M | −$13.4M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −2222.4% | −2051.1% |
| FY24 | −1542.6% | −1366.5% |
| FY23 | −299.9% | −253.3% |
| FY22 | −320.2% | −292.5% |
| FY21 | −388.6% | −379.9% |
| FY20 | −407.5% | −551.6% |
| FY19 | −943.1% | −919% |
| FY18 | −1415.4% | −1405% |
| FY17 | −1025.9% | −1046.1% |
| FY16 | −726.1% | −760.2% |
| FY15 | −1142.8% | −1233.7% |
| FY14 | - | - |
| FY13 | −1820.3% | −2151.8% |
| FY12 | −507.8% | −533.3% |
| FY11 | −1136.2% | −1147.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$112M |
| FY24 | −$123.6M |
| FY23 | −$138.4M |
| FY22 | −$283.8M |
| FY21 | −$213.6M |
| FY20 | −$44.2M |
| FY19 | −$90.6M |
| FY18 | −$41M |
| FY17 | −$38.5M |
| FY16 | −$30.3M |
| FY15 | −$19.9M |
| FY14 | −$23.3M |
| FY13 | −$15.6M |
| FY12 | −$14M |
| FY11 | −$12.1M |
- Fate Therapeutics
- Healthcare median
Show the numbers
| Year | Fate Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −2051.1% | −30.6% |
| FY24 | −1366.5% | −47% |
| FY23 | −253.3% | −58% |
| FY22 | −292.5% | −80.4% |
| FY21 | −379.9% | −71.8% |
| FY20 | −551.6% | −62.2% |
| FY19 | −919% | −46.2% |
| FY18 | −1405% | −49.6% |
| FY17 | −1046.1% | −45.9% |
| FY16 | −760.2% | −36% |
| FY15 | −1233.7% | −37.8% |
| FY14 | - | −35.5% |
| FY13 | −2151.8% | −37.1% |
| FY12 | −533.3% | −29.1% |
| FY11 | −1147.6% | −27.9% |